We also found that 28.6% (2/7) of patients with SCLC (≥second line) and 33.3% (2/6) of patients with gynecologic tumors achieved PR, which was higher than single anti-PD-1 regimen in the similar settings (13.7% for SCLC [17] and<15% for gynecologic tumors [18]). Here, PDCD1 is linked to female reproductive system neoplasm.